Krsnaa Diagnostics Ltd's Q4FY25 Quarterly Results
- 13 May 2025
Result Summary
- Krsnaa Diagnostics Ltd reported a 7.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 22.6%.
- Its expenses for the quarter were down by 6.5% QoQ and up 28.1% YoY.
- The net profit decreased 3.6% QoQ and decreased 1.0% YoY.
- The earnings per share (EPS) of Krsnaa Diagnostics Ltd stood at 5.7 during Q4FY25.
Financial Statments for Q4FY25
Total Income | 170.62 | 183.75 | 139.15 | -7.1% | 22.6% |
Total Expenses | 148.02 | 158.27 | 115.58 | -6.5% | 28.1% |
Profit Before Tax | 22.60 | 25.48 | 23.58 | -11.3% | -4.2% |
Tax | 3.88 | 6.06 | 4.66 | -36.0% | -16.7% |
Profit After Tax | 18.73 | 19.42 | 18.92 | -3.6% | -1.0% |
Earnings Per Share | 5.70 | 5.90 | 5.90 | -3.4% | -3.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Krsnaa Diagnostics Ltd is a company primarily engaged in the provision of diagnostic and related healthcare services. The company operates in the healthcare industry, focusing on offering a range of diagnostic services including imaging, pathology, and radiology. As of the data available up to October 2023, Krsnaa Diagnostics Ltd has been noted for its extensive network of diagnostic centers across various regions, aiming to provide accessible healthcare services. Recent major developments for the company are not detailed here, but it continues to focus on expanding its services and improving healthcare accessibility.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Krsnaa Diagnostics Ltd reported a total income of ₹170.62 crores. This represents a decrease of 7.1% compared to the previous quarter (Q3FY25), where total income was ₹183.75 crores. However, when compared to the same quarter in the previous fiscal year (Q4FY24), there is an increase of 22.6%, as the total income for that period was ₹139.15 crores. This data points to a notable year-over-year growth in revenue, despite a quarter-over-quarter decline.
Profitability
During Q4FY25, Krsnaa Diagnostics Ltd recorded a profit before tax (PBT) of ₹22.60 crores, which is a decline of 11.3% from the previous quarter's PBT of ₹25.48 crores. Compared to the same quarter the previous year, PBT decreased by 4.2% from ₹23.58 crores. The profit after tax (PAT) for Q4FY25 was ₹18.73 crores, showing a slight decrease of 3.6% from the previous quarter's PAT of ₹19.42 crores and a marginal decrease of 1.0% from ₹18.92 crores in Q4FY24. The earnings per share (EPS) in Q4FY25 stood at ₹5.70, representing a decrease both quarter-over-quarter and year-over-year by 3.4%.
Operating Metrics
For the fourth quarter of fiscal year 2025, total expenses were ₹148.02 crores, showing a reduction of 6.5% compared to the previous quarter's expenses of ₹158.27 crores. Year-over-year, total expenses increased by 28.1% from ₹115.58 crores in Q4FY24. Tax expenses for the quarter were ₹3.88 crores, marking a substantial decrease of 36.0% from ₹6.06 crores in Q3FY25, and a 16.7% decrease from ₹4.66 crores in Q4FY24. The financial data points to a decrease in the tax burden quarter-over-quarter and year-over-year, which contrasts with the trends observed in the revenue and profitability metrics.
FAQs
Krsnaa Diagnostics Ltd announced its Q1 FY 2025-26 results on 14 August, 2025.
Krsnaa Diagnostics Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Krsnaa Diagnostics Ltd Q1 FY 2025-26 results include:
- Revenue: ₹196.93 crore
- Net Profit: ₹20.52 crore
- EBITDA: ₹55.35 crore
- Year-over-Year Growth: 10.9%
- Quarter-over-Quarter Growth: 15.4%
Krsnaa Diagnostics Ltd reported a net profit of ₹20.52 crore in Q1 FY 2025-26, reflecting a 14.5% year-over-year growth.
Krsnaa Diagnostics Ltd posted a revenue of ₹196.93 crore in Q1 FY 2025-26.